Royalty Pharma plc (RPRX)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Cystic Fibrosis Franchise Revenue	845.05M	828.18M	826.21M
Cystic Fibrosis Franchise Revenue Growth	2.04%	0.24%	-3.06%
Evrysdi Revenue	210.91M	206.97M	224.43M
Evrysdi Revenue Growth	1.90%	-7.78%	129.61%
Trelegy Revenue	158.40M	154.10M	146.92M
Trelegy Revenue Growth	2.79%	4.89%	14.74%
Tremfya Revenue	161.50M	152.94M	147.14M
Tremfya Revenue Growth	5.60%	3.94%	-1.72%
Voranigo Revenue	167.68M	154.42M	46.15M
Voranigo Revenue Growth	8.59%	234.58%	-
Tysabri Revenue	112.52M	116.88M	124.82M
Tysabri Revenue Growth	-3.73%	-6.36%	-25.50%
Other Products Revenue	660.60M	647.67M	633.76M
Other Products Revenue Growth	2.00%	2.20%	0.72%
Total Income from Financial Royalty Assets	2.32B	2.26B	2.15B
Total Income from Financial Royalty Assets Growth	2.46%	5.20%	-2.20%
Other Royalty Income and Revenue	123.87M	117.04M	114.15M
Other Royalty Income and Revenue Growth	5.83%	2.53%	-27.20%
Revenue (Other)	-167.68M	-154.42M	-46.15M
Revenue (Total)	2.44B	2.38B	2.26B
Revenue (Total) Growth	2.62%	5.06%	-3.86%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Portfolio Receipts	3.34B	3.25B	2.80B
Portfolio Receipts Growth	2.65%	16.17%	-8.11%

Updated May 6, 2026. Data Source: Fiscal.ai.